Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 672Carcinoma, Non-Small-Cell Lung 461Prostatic Neoplasms 390Neoplasms 382Lung Neoplasms 266Multiple Myeloma 246Colorectal Neoplasms 235Neoplasm Metastasis 217Melanoma 203Ovarian Neoplasms 166Leukemia, Myeloid, Acute 166Pancreatic Neoplasms 155Squamous Cell Carcinoma of Head and Neck 141Carcinoma, Renal Cell 141Lymphoma 137Brain Neoplasms 132Leukemia, Lymphocytic, Chronic, B-Cell 126Glioblastoma 126Recurrence 124Lymphoma, Non-Hodgkin 123Carcinoma, Hepatocellular 119Head and Neck Neoplasms 115Urinary Bladder Neoplasms 111Triple Negative Breast Neoplasms 110Stomach Neoplasms 110Precursor Cell Lymphoblastic Leukemia-Lymphoma 105Uterine Cervical Neoplasms 102Hematologic Neoplasms 100Lymphoma, Follicular 96Sarcoma 95

Interventions

luprolide acetate gel depot 1exemestane 1darolutamide 1X-Rays 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Leuprolide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Granulosa cell tumor of the ovary × 1 year × Clear all
NCT06169124 2026-05-13

Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
37 enrolled

Granulosa cell tumor of the ovary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡